UPDATE: Cryoport (CYRX) Misses Q3 EPS by 14c; Trims FY16 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Cryoport Reports 50% Revenue Growth for the Third Quarter of Fiscal Year 2016
February 8, 2016 9:02 AM ESTIRVINE, Calif., Feb. 8, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company") today announced financial results for the three and nine-month periods ended December 31, 2015.
Commenting on the third quarter results, Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "We grew revenue by 50% for the third quarter. This growth was primarily driven by the addition of a significant number of new biopharma clients, including eight new clinical trial programs. Even though biopharma revenue was up 80% year-over-year, these results were well below our expectations due to delays in program... More
